IV. Fajdigovi dnevi KRONIýNA BOLEýINA, SLADKORNA BOLEZEN ...

Kržan M. Interakcije med analgetiki in drugimi zdravili ter zaužitimi snovmi
sulindaka, zmanjšujejo izlo�anje litijevih soli, zato je potrebno ob hkratni uporabi nadzorovati koncentracijo
litija v plazmi. Salicilati ovirajo izlo�anje metotreksata in bistveno pove�ajo njegovo koncentracijo v plazmi,
zato naj se ne bi uporabljali med kemoterapijo (16).
Sklep
Zdravljenje bole�ine je ena najpomebnejših nalog vsakega zdravnika. Poznavanje mehanizmov delovanja
analgeti�nih zdravil ter interakcij med zdravili, ki se odražajo v ve�ini primerov z ve�jim analgeti�nim u�inkov
in relativno nizko pojavnostjo resnih neželenih u�inkov, je nujno, da se prebrodi strah pred ve�jim
predpisovanjem narkoti�nih analgetikov in njihovih kombinacij pri zdravljenju mo�ne bole�ine.
Literatura
1. Wright JM. Drug interactions. In: Carrutherrs SG, Hoffman BB, Melmon KL, Nierenberg DW (eds) Melmon and
Morrelli´s Clinical Pharmacology. Fourth Edition. Mc Graw Hill New York 2000: pp1257-66.
2. Alexander SPH, Mathie A, Peters JA (eds) Trends in Pharmacological Sciences 2001 Nomenclature Supplement.
Twelfth Edition. Elsevier Science London 2001: pp 77-8.
3. Dhawan BN, Cesselin F, Raghubir R, Reisine, Bradley PB, Portoghese PS, Hamon M. International Union of
Pharmacology. XII. Classification of opioid receptors Pharmacol Rev 1996; 48:567-92.
4. Liu JG, Anand KJ. Protein kinases modulate the cellular adaptations associated with opioid tolerance and dependence.
Brain Res Brain Res Rev 2001; 38: 1-19.
5. Rang HP, Dale MM, Ritter. Pharmacology- Fourth Edition. Churchill Livingstone Edinburgh 1999: pp 229-47.
6. Christie MJ, Vaughan CW, Ingram SL. Opioids, NSAIDs and 5-lipooxygenase inhibitors act synrgistically in brain via
arachidonic acid metabolism. Inflamm Res 1999; 48: 1-4.
7. Martin TJ, Eisenach JC. Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther
2001; 299: 811-7.
8. MacPherson RD. The pharmacological basis of contemporary pain management. Pharmacol Ther 2000; 88: 163-85.
9. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid
responsiveness. J Pain Sympt Managm 2001; 21: 338-54.
10. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE (eds) Goodman &
Gilman´s the pharmacological basis of therapeutics. Tenth Edition. McGraw-Hill New York 2001; pp 52147.
11. Arcioni R, della Rocca M, Romano S, Romano R, Pietropaoli P, Gasparetto A. Ondansetron inhibits the nalgesic effect
of tramadol: a posible 5-HT3 spinal receptor involvement in acute pain in humans. Anesth Analg 2002; 94: 1553-7.
12. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997; 54: 643-52.
13. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin
anticoagulation. J Am Med Assoc 1998; 279: 657-62.
14. Vincent-Viry M, Fournier B, GalteauMM. The effects of drinking and smoking on the CYP2D6 metabolic capacity.
Drug Metab Dispos 2000; 28: 617-9.
15. Caraco Y, Sheller J, Wood AJ. Impact of ethnic origin and quinidine coadministration on codeine´s disposition and
pharmacokinetic effects. J Pharmacol Exp Ther 1999; 290: 413-22.
16. Twycross R, Wilcock A, Thorp S. Palliative care formulary. Radcliffe Medical Press Oxon 1998, pp 85-124.
4. Fajdigovi dnevi, Kranjska Gora, 11. – 12. 10. 2002 12